Humanized Anti-pacap antibody and uses thereof
A humanized anti-PACAP antibody, Abl, provides a safer and more effective treatment for migraine by inhibiting PACAP signaling, addressing the limitations of current pharmacological treatments and improving migraine prevention.
WO2026120069A1PCT designated stage Publication Date: 2026-06-11H LUNDBECK AS
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- H LUNDBECK AS
- Filing Date
- 2025-12-04
- Publication Date
- 2026-06-11
Smart Images
Figure EP2025085473_11062026_PF_FP_ABST
Abstract
The present invention is directed to an antibody having binding specificity for PACAP for the treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and / or neuronal activation, would be therapeutically beneficial.
Need to check novelty before this filing date? Find Prior Art